Ionis Pharmaceuticals Sees 83.3% EPS Drop to $1.21 Loss, Revenue Falls 31.5%
Ionis Pharmaceuticals is projected to post a $1.21 per share loss for the quarter ended December 2025, marking an 83.3% year-over-year decline. Revenue is forecast at $155.6 million, down 31.5%, while analysts’ revisions lifted consensus estimates by 0.8%, yielding a +17.84% Earnings ESP.
1. Q4 2025 Estimates
Ionis Pharmaceuticals is expected to report a loss of $1.21 per share for Q4 2025, representing an 83.3% year-over-year decline in earnings on projected revenues of $155.58 million, down 31.5% from the prior year.
2. Estimate Revisions and Earnings ESP
Over the past 30 days, consensus EPS estimates were revised upward by 0.8%, resulting in a +17.84% Earnings ESP, indicating analysts’ improved near-term outlook despite the company’s Hold rating.
3. Historical Earnings Surprises
Ionis has beaten consensus EPS estimates in each of the trailing four quarters, showcasing a pattern of positive surprises that may support another upside beat in the upcoming report.